Compagnie Lombard Odier SCmA’s NovoCure NVCR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $70K | Hold |
3,930
| – | – | ﹤0.01% | 308 |
|
|
2025
Q1 | $70K | Hold |
3,930
| – | – | ﹤0.01% | 333 |
|
|
2024
Q4 | $117K | Hold |
3,930
| – | – | ﹤0.01% | 282 |
|
|
2024
Q3 | $61.4K | Hold |
3,930
| – | – | ﹤0.01% | 325 |
|
|
2024
Q2 | $67.3K | Hold |
3,930
| – | – | ﹤0.01% | 314 |
|
|
2024
Q1 | $61.4K | Hold |
3,930
| – | – | ﹤0.01% | 341 |
|
|
2023
Q4 | $58.7K | Hold |
3,930
| – | – | ﹤0.01% | 394 |
|
|
2023
Q3 | $63.5K | Hold |
3,930
| – | – | ﹤0.01% | 400 |
|
|
2023
Q2 | $163K | Hold |
3,930
| – | – | ﹤0.01% | 300 |
|
|
2023
Q1 | $236K | Buy |
3,930
+850
| +28% | +$51.1K | 0.01% | 264 |
|
|
2022
Q4 | $226K | Hold |
3,080
| – | – | 0.01% | 276 |
|
|
2022
Q3 | $234K | Hold |
3,080
| – | – | 0.01% | 280 |
|
|
2022
Q2 | $214K | Hold |
3,080
| – | – | 0.01% | 285 |
|
|
2022
Q1 | $255K | Hold |
3,080
| – | – | 0.01% | 279 |
|
|
2021
Q4 | $231K | Buy |
3,080
+40
| +1% | +$3K | ﹤0.01% | 338 |
|
|
2021
Q3 | $354K | Hold |
3,040
| – | – | 0.01% | 287 |
|
|
2021
Q2 | $674K | Hold |
3,040
| – | – | 0.01% | 198 |
|
|
2021
Q1 | $402K | Buy |
3,040
+40
| +1% | +$5.29K | 0.01% | 307 |
|
|
2020
Q4 | $519K | Hold |
3,000
| – | – | 0.01% | 216 |
|
|
2020
Q3 | $334K | Hold |
3,000
| – | – | 0.01% | 223 |
|
|
2020
Q2 | $178K | Hold |
3,000
| – | – | 0.01% | 270 |
|
|
2020
Q1 | $202K | Hold |
3,000
| – | – | 0.01% | 239 |
|
|
2019
Q4 | $253K | Hold |
3,000
| – | – | 0.01% | 233 |
|
|
2019
Q3 | $224K | Buy |
+3,000
| New | +$224K | 0.01% | 236 |
|